Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) CEO Acquires $49,753.61 in Stock

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) CEO David P. Luci bought 49,261 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The stock was bought at an average price of $1.01 per share, with a total value of $49,753.61. Following the acquisition, the chief executive officer now directly owns 1,097,458 shares in the company, valued at $1,108,432.58. The trade was a 4.70 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

Acurx Pharmaceuticals Price Performance

NASDAQ ACXP opened at $0.75 on Thursday. The company has a market cap of $12.69 million, a P/E ratio of -0.69 and a beta of -1.71. The stock has a 50-day moving average of $1.19 and a two-hundred day moving average of $1.78. Acurx Pharmaceuticals, Inc. has a 1-year low of $0.68 and a 1-year high of $5.28.

Acurx Pharmaceuticals (NASDAQ:ACXP) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. During the same quarter last year, the firm posted ($0.24) earnings per share. On average, analysts anticipate that Acurx Pharmaceuticals, Inc. will post -0.89 EPS for the current fiscal year.

Hedge Funds Weigh In On Acurx Pharmaceuticals

A hedge fund recently raised its stake in Acurx Pharmaceuticals stock. Prospect Financial Services LLC lifted its stake in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) by 6.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 295,075 shares of the company’s stock after purchasing an additional 16,975 shares during the period. Prospect Financial Services LLC owned about 1.86% of Acurx Pharmaceuticals worth $561,000 at the end of the most recent quarter. Institutional investors own 11.53% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Acurx Pharmaceuticals in a research note on Tuesday, December 10th.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.